27595710|t|The MEssaging for Diabetes Intervention Reduced Barriers to Medication Adherence Among Low-Income, Diverse Adults With Type 2
27595710|a|Nonadherence to diabetes medication is prevalent and costly. MEssaging for Diabetes (MED), a mobile health (mHealth) intervention, identified and addressed user -specific barriers to medication adherence. We assessed whether MED reduced users ' targeted barriers and if barrier reductions were associated with within-participant improvements in adherence or glycemic control (HbA1c). Adults (N = 80) with type 2 diabetes completed self-report measures identifying barriers to adherence at baseline and monthly for 3 months. At each assessment, 17 barriers were assessed and ranked for each user. Each subsequent month, users received daily text messages addressing their 3 highest ranked barriers. Targeted barriers were different for each participant and could change monthly. Paired t-tests assessed within-participant improvement in targeted barriers each month, and nested regression models assessed if changes in a participant's barrier scores were associated with improvements in adherence and HbA1c. Participants were 69% non-white and 82% had incomes <$25K. Average HbA1c was 8.2 Â± 2.0%. Assessment completion rates were 100% at baseline, 59% at 1 month, 30% at 2 months, and 65% at 3 months. The most commonly reported barriers were the cost of medications (76%), believing medications are harmful (58%), and lacking information about medications (53%). Participants ' barrier scores improved each month and barrier improvement predicted adherence assessed via nightly adherence assessment text messages (P < .001). Among participants who completed assessments each month, barrier improvement in months 2 and 3 (P < .05) predicted HbA1c improvement. Iterative, individual tailoring may overcome users ' barriers to adherence. Attrition is a challenge for mHealth interventions among low-income patients.
27595710	4	26	MEssaging for Diabetes	T058	C1254363
27595710	27	39	Intervention	T061	C0184661
27595710	48	56	Barriers	T080	C0679881
27595710	60	80	Medication Adherence	T033	C2364172
27595710	87	97	Low-Income	T033	C1331016
27595710	107	113	Adults	T100	C0001675
27595710	119	125	Type 2	T047	C0011860
27595710	126	138	Nonadherence	T033	C0746935
27595710	142	150	diabetes	T047	C0011847
27595710	151	161	medication	T058	C2081612
27595710	187	209	MEssaging for Diabetes	T058	C1254363
27595710	211	214	MED	T058	C1254363
27595710	219	232	mobile health	T058	C2718080
27595710	234	241	mHealth	T058	C2718080
27595710	243	255	intervention	T061	C0184661
27595710	282	286	user	T098	C1706077
27595710	297	305	barriers	T080	C0679881
27595710	309	329	medication adherence	T033	C2364172
27595710	351	354	MED	T058	C1254363
27595710	363	368	users	T098	C1706077
27595710	380	388	barriers	T080	C0679881
27595710	396	403	barrier	T080	C0679881
27595710	436	454	within-participant	T098	C0679646
27595710	471	480	adherence	T169	C1510802
27595710	484	500	glycemic control	T080	C0205556
27595710	502	507	HbA1c	T116,T123	C0019018
27595710	510	516	Adults	T100	C0001675
27595710	531	546	type 2 diabetes	T047	C0011860
27595710	590	598	barriers	T080	C0679881
27595710	602	611	adherence	T169	C1510802
27595710	628	635	monthly	T079	C0332177
27595710	642	648	months	T079	C0439231
27595710	658	668	assessment	T058	C0220825
27595710	673	681	barriers	T080	C0679881
27595710	716	720	user	T098	C1706077
27595710	738	743	month	T079	C0439231
27595710	745	750	users	T098	C1706077
27595710	766	779	text messages	T170	C3178910
27595710	814	822	barriers	T080	C0679881
27595710	833	841	barriers	T080	C0679881
27595710	866	877	participant	T098	C0679646
27595710	895	902	monthly	T079	C0332177
27595710	911	918	t-tests	T170	C0871472
27595710	928	946	within-participant	T098	C0679646
27595710	971	979	barriers	T080	C0679881
27595710	985	990	month	T079	C0439231
27595710	1003	1020	regression models	T170	C3161035
27595710	1046	1059	participant's	T098	C0679646
27595710	1112	1121	adherence	T169	C1510802
27595710	1126	1131	HbA1c	T116,T123	C0019018
27595710	1133	1145	Participants	T098	C0679646
27595710	1200	1205	HbA1c	T116,T123	C0019018
27595710	1282	1287	month	T079	C0439231
27595710	1298	1304	months	T079	C0439231
27595710	1319	1325	months	T079	C0439231
27595710	1354	1362	barriers	T080	C0679881
27595710	1372	1376	cost	T081	C0010186
27595710	1380	1391	medications	T058	C2081612
27595710	1409	1420	medications	T058	C2081612
27595710	1470	1481	medications	T058	C2081612
27595710	1489	1501	Participants	T098	C0679646
27595710	1504	1511	barrier	T080	C0679881
27595710	1533	1538	month	T079	C0439231
27595710	1543	1550	barrier	T080	C0679881
27595710	1573	1582	adherence	T169	C1510802
27595710	1604	1613	adherence	T169	C1510802
27595710	1625	1638	text messages	T170	C3178910
27595710	1657	1669	participants	T098	C0679646
27595710	1701	1706	month	T079	C0439231
27595710	1708	1715	barrier	T080	C0679881
27595710	1731	1737	months	T079	C0439231
27595710	1766	1771	HbA1c	T116,T123	C0019018
27595710	1830	1835	users	T098	C1706077
27595710	1838	1846	barriers	T080	C0679881
27595710	1850	1859	adherence	T169	C1510802
27595710	1890	1897	mHealth	T058	C2718080
27595710	1898	1911	interventions	T061	C0184661
27595710	1918	1928	low-income	T033	C1331016
27595710	1929	1937	patients	T101	C0030705